-
1
-
-
84856019858
-
The DNA damage response and cancer therapy
-
Lord CJ, Ashworth A. 2012. The DNA damage response and cancer therapy. Nature 481:287-94
-
(2012)
Nature
, vol.481
, pp. 287-294
-
-
Lord, C.J.1
Ashworth, A.2
-
2
-
-
84890816405
-
Finding effective cancer therapies through loss of function genetic screens
-
Bernards R. 2014. Finding effective cancer therapies through loss of function genetic screens. Curr. Opin. Genet. Dev. 24C:23-29
-
(2014)
Curr. Opin. Genet. Dev.
, vol.24 C
, pp. 23-29
-
-
Bernards, R.1
-
3
-
-
0037025173
-
Cancer Addiction to oncogenes-The Achilles heel of cancer
-
Weinstein IB. 2002. Cancer. Addiction to oncogenes-The Achilles heel of cancer. Science 297:63-64
-
(2002)
Science
, vol.297
, pp. 63-64
-
-
Weinstein, I.B.1
-
4
-
-
58149398623
-
Translation of the Philadelphia chromosome into therapy for CML
-
Druker BJ. 2008. Translation of the Philadelphia chromosome into therapy for CML. Blood 112:4808-17
-
(2008)
Blood
, vol.112
, pp. 4808-4817
-
-
Druker, B.J.1
-
5
-
-
78649390831
-
Treatment of HER2-overexpressing breast cancer
-
Baselga J. 2010. Treatment of HER2-overexpressing breast cancer. Ann. Oncol. 21(Suppl 7):vii36-40
-
(2010)
Ann. Oncol.
, vol.21
, pp. vii36-vii40
-
-
Baselga, J.1
-
6
-
-
84872625067
-
Genetics of natural populations XIII. Recombination and variability in populations of Drosophila pseudoobscura
-
Dobzhansky T. 1946. Genetics of natural populations. XIII. Recombination and variability in populations of Drosophila pseudoobscura. Genetics 31:269-90
-
(1946)
Genetics
, vol.31
, pp. 269-290
-
-
Dobzhansky, T.1
-
7
-
-
41349102391
-
Evolutionary plasticity of genetic interaction networks
-
Tischler J, Lehner B, Fraser AG. 2008. Evolutionary plasticity of genetic interaction networks. Nat. Genet. 40:390-91
-
(2008)
Nat. Genet.
, vol.40
, pp. 390-391
-
-
Tischler, J.1
Lehner, B.2
Fraser, A.G.3
-
8
-
-
0035830860
-
Principles for the buffering of genetic variation
-
Hartman JLT, Garvik B, Hartwell L. 2001. Principles for the buffering of genetic variation. Science 291:1001-4
-
(2001)
Science
, vol.291
, pp. 1001-1004
-
-
Hartman, J.L.T.1
Garvik, B.2
Hartwell, L.3
-
9
-
-
84891301320
-
Causes and consequences of replication stress
-
Zeman MK, Cimprich KA. 2014. Causes and consequences of replication stress. Nat. Cell Biol. 16:2-9
-
(2014)
Nat. Cell Biol.
, vol.16
, pp. 2-9
-
-
Zeman, M.K.1
Cimprich, K.A.2
-
10
-
-
0030667434
-
Integrating genetic approaches into the discovery of anticancer drugs
-
Hartwell LH, Szankasi P, Roberts CJ, et al. 1997. Integrating genetic approaches into the discovery of anticancer drugs. Science 278:1064-68
-
(1997)
Science
, vol.278
, pp. 1064-1068
-
-
Hartwell, L.H.1
Szankasi, P.2
Roberts, C.J.3
-
11
-
-
25444497278
-
The concept of synthetic lethality in the context of anticancer therapy
-
Kaelin Jr. WG. 2005. The concept of synthetic lethality in the context of anticancer therapy. Nat. Rev. Cancer 5:689-98
-
(2005)
Nat. Rev. Cancer
, vol.5
, pp. 689-698
-
-
Kaelin, W.G.1
-
12
-
-
84896995635
-
Two decades after BRCA: Setting paradigms in personalized cancer care and prevention
-
Couch FJ, Nathanson KL, Offit K. 2014. Two decades after BRCA: setting paradigms in personalized cancer care and prevention. Science 343:1466-70
-
(2014)
Science
, vol.343
, pp. 1466-1470
-
-
Couch, F.J.1
Nathanson, K.L.2
Offit, K.3
-
13
-
-
84897003294
-
The race to clone BRCA1
-
King MC. 2014. 'The race' to clone BRCA1. Science 343:1462-65
-
(2014)
Science
, vol.343
, pp. 1462-1465
-
-
King, M.C.1
-
14
-
-
84896940791
-
Cancer suppression by the chromosome custodians BRCA1 and BRCA2
-
Venkitaraman AR. 2014. Cancer suppression by the chromosome custodians, BRCA1 and BRCA2. Science 343:1470-75
-
(2014)
Science
, vol.343
, pp. 1470-1475
-
-
Venkitaraman, A.R.1
-
15
-
-
0035801472
-
Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences
-
Tutt A, Bertwistle D, Valentine J, et al. 2001. Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences. EMBO J. 20:4704-16
-
(2001)
EMBO J.
, vol.20
, pp. 4704-4716
-
-
Tutt, A.1
Bertwistle, D.2
Valentine, J.3
-
16
-
-
33746100822
-
Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer
-
Tutt AN, Lord CJ, McCabe N, et al. 2005. Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer. Cold Spring Harb. Symp. Quant. Biol. 70:139-48
-
(2005)
Cold Spring Harb. Symp. Quant. Biol.
, vol.70
, pp. 139-148
-
-
Tutt, A.N.1
Lord, C.J.2
McCabe, N.3
-
17
-
-
38149059734
-
Triple negative' breast cancer: A new area for phase III breast cancer clinical trials
-
Kilburn LS. 2008. 'Triple negative' breast cancer: a new area for phase III breast cancer clinical trials. Clin. Oncol. 20:35-39
-
(2008)
Clin. Oncol.
, vol.20
, pp. 35-39
-
-
Kilburn, L.S.1
-
18
-
-
17244373777
-
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
-
Farmer H, McCabe N, Lord CJ, et al. 2005. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434:917-21
-
(2005)
Nature
, vol.434
, pp. 917-921
-
-
Farmer, H.1
McCabe, N.2
Lord, C.J.3
-
19
-
-
17244375049
-
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
-
Bryant HE, Schultz N, Thomas HD, et al. 2005. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434:913-17
-
(2005)
Nature
, vol.434
, pp. 913-917
-
-
Bryant, H.E.1
Schultz, N.2
Thomas, H.D.3
-
20
-
-
0026507413
-
Role of poly(ADP-ribose) formation in DNA repair
-
Satoh MS, Lindahl T. 1992. Role of poly(ADP-ribose) formation in DNA repair. Nature 356:356-58
-
(1992)
Nature
, vol.356
, pp. 356-358
-
-
Satoh, M.S.1
Lindahl, T.2
-
21
-
-
35748970514
-
PARP inhibitor development for systemic cancer targeting
-
Zaremba T, Curtin NJ. 2007. PARP inhibitor development for systemic cancer targeting. Anticancer Agents Med. Chem. 7:515-23
-
(2007)
Anticancer Agents Med. Chem.
, vol.7
, pp. 515-523
-
-
Zaremba, T.1
Curtin, N.J.2
-
22
-
-
59449085305
-
Phase i study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors
-
Plummer R, Jones C, Middleton M, et al. 2008. Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin. Cancer Res. 14:7917-23
-
(2008)
Clin. Cancer Res.
, vol.14
, pp. 7917-7923
-
-
Plummer, R.1
Jones, C.2
Middleton, M.3
-
23
-
-
67650471685
-
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers
-
Fong PC, BossDS, YapTA, et al. 2009. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361:123-34
-
(2009)
N. Engl. J. Med.
, vol.361
, pp. 123-134
-
-
Fong, P.C.1
Boss, D.S.2
Yap, T.A.3
-
24
-
-
77954032829
-
Poly(ADP)-ribose polymerase inhibition: Frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval
-
Fong PC, Yap TA, Boss DS, et al. 2010. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J. Clin. Oncol. 28:2512-19
-
(2010)
J. Clin. Oncol.
, vol.28
, pp. 2512-2519
-
-
Fong, P.C.1
Yap, T.A.2
Boss, D.S.3
-
25
-
-
77955019276
-
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: A proof-of-concept trial
-
Tutt A, Robson M, Garber JE, et al. 2010. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376:235-44
-
(2010)
Lancet
, vol.376
, pp. 235-244
-
-
Tutt, A.1
Robson, M.2
Garber, J.E.3
-
26
-
-
77955039099
-
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: A proof-of-concept trial
-
AudehMW, Carmichael J, Penson RT, et al. 2010. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376:245-51
-
(2010)
Lancet
, vol.376
, pp. 245-251
-
-
Audeh, M.W.1
Carmichael, J.2
Penson, R.T.3
-
27
-
-
80052389761
-
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: A phase 2, multicentre, open-label, non-randomised study
-
Gelmon KA, Tischkowitz M, Mackay H, et al. 2011. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 12:852-61
-
(2011)
Lancet Oncol.
, vol.12
, pp. 852-861
-
-
Gelmon, K.A.1
Tischkowitz, M.2
MacKay, H.3
-
29
-
-
84859523588
-
Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer
-
Ledermann J, Harter P, Gourley C, et al. 2012. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N. Engl. J. Med. 366:1382-92
-
(2012)
N. Engl. J. Med.
, vol.366
, pp. 1382-1392
-
-
Ledermann, J.1
Harter, P.2
Gourley, C.3
-
30
-
-
84885420701
-
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (SOC) and a BRCA mutation (BRCAm)
-
Suppl.
-
Ledermann JA, Harter P, Gourley C, et al. 2013. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (SOC) and a BRCA mutation (BRCAm). J. Clin. Oncol. 31(Suppl.):5505
-
(2013)
J. Clin. Oncol.
, vol.31
, pp. 5505
-
-
Ledermann, J.A.1
Harter, P.2
Gourley, C.3
-
31
-
-
0029089917
-
Potential chemotherapeutic activity of 4-iodo-3-nitrobenzamide Metabolic reduction to the 3-nitroso derivative and induction of cell death in tumor cells in culture
-
Mendeleyev J, Kirsten E, Hakam A, et al. 1995. Potential chemotherapeutic activity of 4-iodo-3-nitrobenzamide. Metabolic reduction to the 3-nitroso derivative and induction of cell death in tumor cells in culture. Biochem. Pharmacol. 50:705-14
-
(1995)
Biochem. Pharmacol.
, vol.50
, pp. 705-714
-
-
Mendeleyev, J.1
Kirsten, E.2
Hakam, A.3
-
32
-
-
78751610848
-
Iniparib plus chemotherapy in metastatic triplenegative breast cancer
-
O'Shaughnessy J, Osborne C, Pippen JE, et al. 2011. Iniparib plus chemotherapy in metastatic triplenegative breast cancer. N. Engl. J. Med. 364:205-14
-
(2011)
N. Engl. J. Med.
, vol.364
, pp. 205-214
-
-
O'shaughnessy, J.1
Osborne, C.2
Pippen, J.E.3
-
33
-
-
84894684013
-
Downfall of iniparib: A PARP inhibitor that doesn't inhibit PARP after all
-
djt447
-
Sinha G. 2014. Downfall of iniparib: a PARP inhibitor that doesn't inhibit PARP after all. J. Natl. Cancer Inst. 106:djt447
-
(2014)
J. Natl. Cancer Inst.
, vol.106
-
-
Sinha, G.1
-
34
-
-
84889595095
-
Appraising iniparib, the PARP inhibitor that never was-What must we learn?
-
Mateo J, Ong M, Tan DS, et al. 2013. Appraising iniparib, the PARP inhibitor that never was-What must we learn?. Nat. Rev. Clin. Oncol. 10:688-96
-
(2013)
Nat. Rev. Clin. Oncol.
, vol.10
, pp. 688-696
-
-
Mateo, J.1
Ong, M.2
Tan, D.S.3
-
35
-
-
84862907868
-
Iniparib nonselectivelymodifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor
-
LiuX, Shi Y, Maag DX, et al. 2012. Iniparib nonselectivelymodifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor. Clin. Cancer Res. 18:510-23
-
(2012)
Clin. Cancer Res.
, vol.18
, pp. 510-523
-
-
Liux Shi, Y.1
Maag, D.X.2
-
36
-
-
84880316545
-
First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors
-
Suppl.
-
De Bono JS, Mina LA, Gonzalez-Hernandez M, et al. 2013. First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors. J. Clin. Oncol. 31(Suppl.):2580
-
(2013)
J. Clin. Oncol.
, vol.31
, pp. 2580
-
-
De Bono, J.S.1
Mina, L.A.2
Gonzalez-Hernandez, M.3
-
37
-
-
84880777712
-
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: A phase 1 dose-escalation trial
-
Sandhu SK, SchelmanWR, WildingG, et al. 2013. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol. 14:882-92
-
(2013)
Lancet Oncol.
, vol.14
, pp. 882-892
-
-
Sandhu, S.K.1
Schelman, W.R.2
Wilding, G.3
-
38
-
-
84892965735
-
Phase 1 study of continuous oral rucaparib: Analysis of patient subgroup with ovarian/peritoneal cancer
-
Suppl.
-
Kristeleit RBH, Lorusso P, Patel M, et al. 2013. Phase 1 study of continuous oral rucaparib: analysis of patient subgroup with ovarian/peritoneal cancer. J. Clin. Oncol. 31(Suppl.):2585
-
(2013)
J. Clin. Oncol.
, vol.31
, pp. 2585
-
-
Kristeleit, R.B.H.1
Lorusso, P.2
Patel, M.3
-
39
-
-
80355136313
-
Phase II trial of the poly(ADP-ribose) polymerase (PARP) inhibitor AG-014699 in BRCA 1 and 2-mutated, advanced ovarian and/or locally advanced or metastatic breast cancer
-
Suppl.
-
Drew Y, Ledermann JA, Jones A, et al. 2011. Phase II trial of the poly(ADP-ribose) polymerase (PARP) inhibitor AG-014699 in BRCA 1 and 2-mutated, advanced ovarian and/or locally advanced or metastatic breast cancer. J. Clin. Oncol. 29(Suppl.):3104
-
(2011)
J. Clin. Oncol.
, vol.29
, pp. 3104
-
-
Drew, Y.1
Ledermann, J.A.2
Jones, A.3
-
40
-
-
84874827306
-
A phase i study of chronically dosed, singleagent veliparib (ABT-888) in patients (pts) with either BRCA 1/2-mutated cancer (BRCA+), platinumrefractory ovarian cancer, or basal-like breast cancer (BRCA-wt)
-
Suppl.
-
Huggins-Puhalla SL, Beumer JH, Appleman LJ, et al. 2012. A phase I study of chronically dosed, singleagent veliparib (ABT-888) in patients (pts) with either BRCA 1/2-mutated cancer (BRCA+), platinumrefractory ovarian cancer, or basal-like breast cancer (BRCA-wt). J. Clin. Oncol. 30(Suppl.):3054
-
(2012)
J. Clin. Oncol.
, vol.30
, pp. 3054
-
-
Huggins-Puhalla, S.L.1
Beumer, J.H.2
Appleman, L.J.3
-
41
-
-
39849097680
-
Resistance to therapy caused by intragenic deletion in BRCA2
-
Edwards SL, Brough R, Lord CJ, et al. 2008. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 451:1111-15
-
(2008)
Nature
, vol.451
, pp. 1111-1115
-
-
Edwards, S.L.1
Brough, R.2
Lord, C.J.3
-
42
-
-
39849106300
-
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
-
SakaiW, Swisher EM, Karlan BY, et al. 2008. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 451:1116-20
-
(2008)
Nature
, vol.451
, pp. 1116-1120
-
-
Sakai, W.1
Swisher, E.M.2
Karlan, B.Y.3
-
43
-
-
80051642095
-
Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas
-
Norquist B, Wurz KA, Pennil CC, et al. 2011. Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J. Clin. Oncol. 29:3008-15
-
(2011)
J. Clin. Oncol.
, vol.29
, pp. 3008-3015
-
-
Norquist, B.1
Wurz, K.A.2
Pennil, C.C.3
-
44
-
-
84872971914
-
Secondarymutations inBRCA2associated with clinical resistance to a PARP inhibitor
-
Barber LJ, Sandhu S, ChenL, et al. 2013. Secondarymutations inBRCA2associated with clinical resistance to a PARP inhibitor. J. Pathol. 229:422-29
-
(2013)
J. Pathol.
, vol.229
, pp. 422-429
-
-
Barber, L.J.1
Sandhu, S.2
Chen, L.3
-
45
-
-
84856013431
-
Clonal evolution in cancer
-
Greaves M, Maley CC. 2012. Clonal evolution in cancer. Nature 481:306-13
-
(2012)
Nature
, vol.481
, pp. 306-313
-
-
Greaves, M.1
Maley, C.C.2
-
46
-
-
84887431012
-
Mechanisms of resistance to therapies targeting BRCA-mutant cancers
-
Lord CJ, Ashworth A. 2013. Mechanisms of resistance to therapies targeting BRCA-mutant cancers. Nat. Med. 19:1381-88
-
(2013)
Nat. Med.
, vol.19
, pp. 1381-1388
-
-
Lord, C.J.1
Ashworth, A.2
-
47
-
-
55949092708
-
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
-
Rottenberg S, Jaspers JE, Kersbergen A, et al. 2008. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc. Natl. Acad. Sci. USA 105:17079-84
-
(2008)
Proc. Natl. Acad. Sci. USA
, vol.105
, pp. 17079-17084
-
-
Rottenberg, S.1
Jaspers, J.E.2
Kersbergen, A.3
-
48
-
-
84872837247
-
Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors
-
Jaspers JE, Kersbergen A, Boon U, et al. 2013. Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. Cancer Discov. 3:68-81
-
(2013)
Cancer Discov.
, vol.3
, pp. 68-81
-
-
Jaspers, J.E.1
Kersbergen, A.2
Boon, U.3
-
49
-
-
84878893538
-
53BP1 mediates productive and mutagenic DNA repair through distinct phosphoprotein interactions
-
Callen E, Di Virgilio M, Kruhlak MJ, et al. 2013. 53BP1 mediates productive and mutagenic DNA repair through distinct phosphoprotein interactions. Cell 153:1266-80
-
(2013)
Cell
, vol.153
, pp. 1266-1280
-
-
Callen, E.1
Di Virgilio, M.2
Kruhlak, M.J.3
-
50
-
-
84868015370
-
Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment
-
Oplustilova L, Wolanin K, Mistrik M, et al. 2012. Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment. Cell Cycle 11:3837-50
-
(2012)
Cell Cycle
, vol.11
, pp. 3837-3850
-
-
Oplustilova, L.1
Wolanin, K.2
Mistrik, M.3
-
51
-
-
84885770237
-
Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance
-
Johnson N, Johnson SF, Yao W, et al. 2013. Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance. Proc. Natl. Acad. Sci. USA 110:17041-46
-
(2013)
Proc. Natl. Acad. Sci. USA
, vol.110
, pp. 17041-17046
-
-
Johnson, N.1
Johnson, S.F.2
Yao, W.3
-
52
-
-
77953291328
-
53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers
-
Bouwman P, Aly A, Escandell JM, et al. 2010. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat. Struct. Mol. Biol. 17:688-95
-
(2010)
Nat. Struct. Mol. Biol.
, vol.17
, pp. 688-695
-
-
Bouwman, P.1
Aly, A.2
Escandell, J.M.3
-
53
-
-
84876715061
-
A genetic screen using the piggyBac transposon in haploid cells identifies Parp1 as a mediator of olaparib toxicity
-
Pettitt SJ, Rehman F, Bajrami I, et al. 2013. A genetic screen using the piggyBac transposon in haploid cells identifies Parp1 as a mediator of olaparib toxicity. PLOS ONE 8:61520
-
(2013)
PLOS ONE
, vol.8
, pp. 61520
-
-
Pettitt, S.J.1
Rehman, F.2
Bajrami, I.3
-
54
-
-
84868221110
-
Trapping of PARP1 and PARP2 by clinical PARP inhibitors
-
Murai J, Huang SY, Das BB, et al. 2012. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. 72:5588-99
-
(2012)
Cancer Res.
, vol.72
, pp. 5588-5599
-
-
Murai, J.1
Huang, S.Y.2
Das, B.B.3
-
55
-
-
84894121635
-
Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib
-
Murai J, Huang SY, Renaud A, et al. 2014. Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Mol. Cancer Ther. 13:433-43
-
(2014)
Mol. Cancer Ther.
, vol.13
, pp. 433-443
-
-
Murai, J.1
Huang, S.Y.2
Renaud, A.3
-
56
-
-
84884576079
-
BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency
-
Shen Y, Rehman FL, Feng Y, et al. 2013. BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency. Clin. Cancer Res. 19:5003-15
-
(2013)
Clin. Cancer Res.
, vol.19
, pp. 5003-5015
-
-
Shen, Y.1
Rehman, F.L.2
Feng, Y.3
-
57
-
-
33748065304
-
Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition
-
McCabe N, Turner NC, Lord CJ, et al. 2006. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 66:8109-15
-
(2006)
Cancer Res.
, vol.66
, pp. 8109-8115
-
-
McCabe, N.1
Turner, N.C.2
Lord, C.J.3
-
58
-
-
33845999615
-
Essential role for nuclear PTEN in maintaining chromosomal integrity
-
ShenWH, Balajee AS, Wang J, et al. 2007. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 128:157-70
-
(2007)
Cell
, vol.128
, pp. 157-170
-
-
Shen, W.H.1
Balajee, A.S.2
Wang, J.3
-
59
-
-
84880710673
-
Nuclear PTEN controls DNA repair and sensitivity to genotoxic stress
-
Bassi C, Ho J, Srikumar T, et al. 2013. Nuclear PTEN controls DNA repair and sensitivity to genotoxic stress. Science 341:395-99
-
(2013)
Science
, vol.341
, pp. 395-399
-
-
Bassi, C.1
Ho, J.2
Srikumar, T.3
-
60
-
-
84874411631
-
Synergistic effect of olaparib with combination of cisplatin on PTEN-deficient lung cancer cells
-
Minami D, Takigawa N, Takeda H, et al. 2013. Synergistic effect of olaparib with combination of cisplatin on PTEN-deficient lung cancer cells. Mol. Cancer Res. 11:140-48
-
(2013)
Mol. Cancer Res.
, vol.11
, pp. 140-148
-
-
Minami, D.1
Takigawa, N.2
Takeda, H.3
-
61
-
-
84901044362
-
ABCB1, ABCG2 and PTEN determine the response of glioblastoma to temozolomide and ABT-888 therapy
-
Lin F, de GooijerMC, Moreno Roig E, et al. 2014. ABCB1, ABCG2 and PTEN determine the response of glioblastoma to temozolomide and ABT-888 therapy. Clin. Cancer Res. 20:2703-13
-
(2014)
Clin. Cancer Res.
, vol.20
, pp. 2703-2713
-
-
Lin, F.1
De Gooijer, M.C.2
Moreno Roig, E.3
-
62
-
-
77149157867
-
Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors
-
Mendes-Pereira AM, Martin SA, Brough R, et al. 2009. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol. Med. 1:315-22
-
(2009)
EMBO Mol. Med.
, vol.1
, pp. 315-322
-
-
Mendes-Pereira, A.M.1
Martin, S.A.2
Brough, R.3
-
63
-
-
84899088512
-
Anti-Tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells
-
Miyasaka A, Oda K, Ikeda Y, et al. 2014. Anti-Tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells. BMC Cancer 14:179-89
-
(2014)
BMC Cancer
, vol.14
, pp. 179-189
-
-
Miyasaka, A.1
Oda, K.2
Ikeda, Y.3
-
64
-
-
84859391984
-
PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma
-
Brenner JC, Feng FY, Han S, et al. 2012. PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma. Cancer Res. 72:1608-13
-
(2012)
Cancer Res.
, vol.72
, pp. 1608-1613
-
-
Brenner, J.C.1
Feng, F.Y.2
Han, S.3
-
65
-
-
79955968629
-
Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer
-
Brenner JC, Ateeq B, Li Y, et al. 2011. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell 19:664-78
-
(2011)
Cancer Cell
, vol.19
, pp. 664-678
-
-
Brenner, J.C.1
Ateeq, B.2
Li, Y.3
-
66
-
-
84859187259
-
Systematic identification of genomic markers of drug sensitivity in cancer cells
-
Garnett MJ, Edelman EJ, Heidorn SJ, et al. 2012. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483:570-75
-
(2012)
Nature
, vol.483
, pp. 570-575
-
-
Garnett, M.J.1
Edelman, E.J.2
Heidorn, S.J.3
-
67
-
-
80054756087
-
The cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes
-
Blazek D, Kohoutek J, Bartholomeeusen K, et al. 2011. The cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes. Genes Dev. 25:2158-72
-
(2011)
Genes Dev.
, vol.25
, pp. 2158-2172
-
-
Blazek, D.1
Kohoutek, J.2
Bartholomeeusen, K.3
-
68
-
-
84897457200
-
Ovarian cancer-Associated mutations disable catalytic activity of CDK12, a kinase that promotes homologous recombination repair and resistance to cisplatin and poly(ADP-ribose) polymerase inhibitors
-
JoshiPM, Sutor SL, Huntoon CJ, KarnitzLM.2014. Ovarian cancer-Associated mutations disable catalytic activity of CDK12, a kinase that promotes homologous recombination repair and resistance to cisplatin and poly(ADP-ribose) polymerase inhibitors. J. Biol. Chem. 289:9247-53
-
(2014)
J. Biol. Chem.
, vol.289
, pp. 9247-9253
-
-
Joshi, P.M.1
Sutor, S.L.2
Huntoon, C.J.3
Karnitz, L.M.4
-
69
-
-
84892712017
-
Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity
-
Bajrami I, Frankum JR, Konde A, et al. 2014. Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity. Cancer Res. 74:287-97
-
(2014)
Cancer Res.
, vol.74
, pp. 287-297
-
-
Bajrami, I.1
Frankum, J.R.2
Konde, A.3
-
70
-
-
84875926116
-
PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells
-
Cheng H, Zhang Z, Borczuk A, et al. 2013. PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells. Carcinogenesis 34:739-49
-
(2013)
Carcinogenesis
, vol.34
, pp. 739-749
-
-
Cheng, H.1
Zhang, Z.2
Borczuk, A.3
-
71
-
-
84888347956
-
Ahigh-Throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer
-
Postel-Vinay S, Bajrami I, Friboulet L, et al. 2013.Ahigh-Throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer. Oncogene 32:5377-87
-
(2013)
Oncogene
, vol.32
, pp. 5377-5387
-
-
Postel-Vinay, S.1
Bajrami, I.2
Friboulet, L.3
-
72
-
-
84880991913
-
Basket studies' will hold intricate data for cancer drug approvals
-
Willyard C. 2013. 'Basket studies' will hold intricate data for cancer drug approvals. Nat. Med. 19:655
-
(2013)
Nat. Med.
, vol.19
, pp. 655
-
-
Willyard, C.1
-
73
-
-
84888434514
-
A reversible gene-Targeting strategy identifies synthetic lethal interactions between MK2 and p53 in the DNA damage response in vivo
-
Morandell S, Reinhardt HC, Cannell IG, et al. 2013. A reversible gene-Targeting strategy identifies synthetic lethal interactions between MK2 and p53 in the DNA damage response in vivo. Cell Rep. 5:868-77
-
(2013)
Cell Rep.
, vol.5
, pp. 868-877
-
-
Morandell, S.1
Reinhardt, H.C.2
Cannell, I.G.3
-
74
-
-
84887933383
-
Depletion of a putatively druggable class of phosphatidylinositol kinases inhibits growth of p53-null tumors
-
Emerling BM, Hurov JB, Poulogiannis G, et al. 2013. Depletion of a putatively druggable class of phosphatidylinositol kinases inhibits growth of p53-null tumors. Cell 155:844-57
-
(2013)
Cell
, vol.155
, pp. 844-857
-
-
Emerling, B.M.1
Hurov, J.B.2
Poulogiannis, G.3
-
75
-
-
84873411856
-
Synthetic lethality of Chk1 inhibition combined with p53 and/or p21 loss during a DNA damage response in normal and tumor cells
-
Origanti S, Cai SR, Munir AZ, et al. 2013. Synthetic lethality of Chk1 inhibition combined with p53 and/or p21 loss during a DNA damage response in normal and tumor cells. Oncogene 32:577-88
-
(2013)
Oncogene
, vol.32
, pp. 577-588
-
-
Origanti, S.1
Cai, S.R.2
Munir, A.Z.3
-
76
-
-
79959376888
-
Selective killing of ATM-or p53-deficient cancer cells through inhibition of ATR
-
Reaper PM, Griffiths MR, Long JM, et al. 2011. Selective killing of ATM-or p53-deficient cancer cells through inhibition of ATR. Nat. Chem. Biol. 7:428-30
-
(2011)
Nat. Chem. Biol.
, vol.7
, pp. 428-430
-
-
Reaper, P.M.1
Griffiths, M.R.2
Long, J.M.3
-
77
-
-
70349559919
-
Tissue regenerative delays and synthetic lethality in adult mice after combined deletion of Atr and Trp53
-
Ruzankina Y, Schoppy DW, Asare A, et al. 2009. Tissue regenerative delays and synthetic lethality in adult mice after combined deletion of Atr and Trp53. Nat. Genet. 41:1144-49
-
(2009)
Nat. Genet.
, vol.41
, pp. 1144-1149
-
-
Ruzankina, Y.1
Schoppy, D.W.2
Asare, A.3
-
78
-
-
79957880430
-
ATR mediates cisplatin resistance in a p53 genotype-specific manner
-
Sangster-Guity N, Conrad BH, Papadopoulos N, Bunz F. 2011. ATR mediates cisplatin resistance in a p53 genotype-specific manner. Oncogene 30:2526-33
-
(2011)
Oncogene
, vol.30
, pp. 2526-2533
-
-
Sangster-Guity, N.1
Conrad, B.H.2
Papadopoulos, N.3
Bunz, F.4
-
79
-
-
84891589759
-
Synthetic lethality screen identifies RPS6KA2 as modifier of epidermal growth factor receptor activity in pancreatic cancer
-
Milosevic N, Kuhnemuth B, Muhlberg L, et al. 2013. Synthetic lethality screen identifies RPS6KA2 as modifier of epidermal growth factor receptor activity in pancreatic cancer. Neoplasia 15:1354-62
-
(2013)
Neoplasia
, vol.15
, pp. 1354-1362
-
-
Milosevic, N.1
Kuhnemuth, B.2
Muhlberg, L.3
-
80
-
-
84860319361
-
The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer
-
KumarMS, Hancock DC, Molina-Arcas M, et al. 2012. The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer. Cell 149:642-55
-
(2012)
Cell
, vol.149
, pp. 642-655
-
-
Kumar, M.S.1
Hancock, D.C.2
Molina-Arcas, M.3
-
81
-
-
84893622205
-
Wild-Type H-And N-Ras promote mutant K-Rasdriven tumorigenesis by modulating the DNA damage response
-
Grabocka E, Pylayeva-Gupta Y, Jones MJ, et al. 2014. Wild-Type H-And N-Ras promote mutant K-Rasdriven tumorigenesis by modulating the DNA damage response. Cancer Cell 25:243-56
-
(2014)
Cancer Cell
, vol.25
, pp. 243-256
-
-
Grabocka, E.1
Pylayeva-Gupta, Y.2
Jones, M.J.3
-
82
-
-
79953283356
-
Genetic interactions in cancer progression and treatment
-
Ashworth A, Lord CJ, Reis-Filho JS. 2011. Genetic interactions in cancer progression and treatment. Cell 145:30-38
-
(2011)
Cell
, vol.145
, pp. 30-38
-
-
Ashworth, A.1
Lord, C.J.2
Reis-Filho, J.S.3
-
83
-
-
84865015653
-
Determination of synthetic lethal interactions inKRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies
-
SteckelM, Molina-Arcas M, Weigelt B, et al. 2012. Determination of synthetic lethal interactions inKRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies. Cell Res. 22:1227-45
-
(2012)
Cell Res.
, vol.22
, pp. 1227-1245
-
-
Steckel, M.1
Molina-Arcas, M.2
Weigelt, B.3
-
84
-
-
84859169877
-
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
-
Barretina J, Caponigro G, Stransky N, et al. 2012. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483:603-7
-
(2012)
Nature
, vol.483
, pp. 603-607
-
-
Barretina, J.1
Caponigro, G.2
Stransky, N.3
-
86
-
-
84893517261
-
Molecular pathways: How can BRCA-mutated tumors become resistant to PARP inhibitors?
-
Bouwman P, Jonkers J. 2014. Molecular pathways: How can BRCA-mutated tumors become resistant to PARP inhibitors?. Clin. Cancer Res. 20:540-47
-
(2014)
Clin. Cancer Res.
, vol.20
, pp. 540-547
-
-
Bouwman, P.1
Jonkers, J.2
|